Solentim Establishes New European Entity

Pharmaceutical Technology Editors

Solentim has announced the expansion of its European operations, with the establishment of a new entity in Ireland.

Solentim, a global provider of workflows for antibody and cell-based therapies, has announced the expansion of its European operations, with the establishment of a new entity in Ireland, in a May 5, 2021 press release.

The Irish entity will enable the company to progress with frictionless business within the European Union (EU), now that the United Kingdom is no longer a member. Additionally, the company has revealed that it has opened a new warehousing and logistics hub in Germany to facilitate customer service in the EU.

“Europe is a fast-growing part of our business both in our core therapeutic antibody business and in new development areas including cell and gene therapies,” said Mark Truesdale, CEO, Solentim, in the press release. “This changing therapeutic landscape, in addition to our launch of two major new products, has rapidly increased demand. We want to be closer and more responsive to the needs of the European market and our office in Ireland will ensure ease of operation for customers while our new warehouse facility in Germany will mean that we can deliver products more quickly and easily.”

Source: Solentim